PDSB
PDS Biotechnology Corporation Common Stock
stockNASDAQ
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology's proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.77 | 2026-09-28 | +56.87% | 6.782 |
| 1M | 0.22 | 2026-09-04 | +446.14% | -11.648 |
| 3M | 0.85 | 2026-07-06 | +42.00% | -1.330 |
| 6M | 0.78 | 2026-04-06 | +53.96% | 1.449 |
| 1Y | 0.96 | 2025-10-06 | +24.80% | 2.339 |
| 2Y | 3.71 | 2024-10-04 | -67.61% | — |
| 5Y | 14.35 | 2021-10-05 | -91.63% | 1.917 |
PDS Biotechnology Corporation Common Stock (NASDAQ:PDSB) stock price today is $1.20, and today's volume is 75,658,602. PDSB is up 60.521% today. The 30 day average volume is 44.21M. PDSB market cap is $87.08M with 72.47M shares outstanding.